BioCentury
ARTICLE | Company News

Merck licenses HCV compounds to Microbiotix

January 3, 2013 2:18 AM UTC

Merck & Co. Inc. (NYSE:MRK) granted Microbiotix Inc. (Worcester, Mass.) exclusive, worldwide rights to two non-nucleoside HCV NS5B inhibitors: MBX-700 and MBX-701. MBX-700 is in Phase I testing, with ...